Skip to search formSkip to main contentSkip to account menu

R-138727

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
Vorapaxar is a first‐in‐class antagonist of the protease‐activated receptor‐1, the primary thrombin receptor on human platelets… 
2016
2016
Analysis of prasugrel active metabolite R-138727 in human plasma: a sensitive, highly selective and fast LC-MS/MS method.
2014
2014
Title ： Hepatic Microsomal Thiol Methyltransferase Is Involved in Stereoselective Methylation of Pharmacologically Active Metabolite of Prasugrel
Prasugrel, a thienopyridine anti-platelet drug, is converted in animals and humans to the pharmacologically active metabolite ( 
2013
2013
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
2011
2011
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12 antagonism
The VerifyNow® P2Y12 (VN-P2Y12) test reports thienopyridine-mediated platelet inhibition relative to a “BASE” channel… 
2010
2010
(Ticlid) are thienopyridine antiplatelet agents. Prasugrel is indicated to reduce the rate of thrombotic cardiovascular events and stent thrombosis in patients with acute coronary syndrome that are…
162 words This article has not been copyedited and formatted. The final version may differ from this version. ABSTRACT A… 
2009
2009
Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs
Prasugrel and clopidogrel are antiplatelet prodrugs that are converted to their respective active metabolites through thiolactone… 
2007
2007
Disposition and metabolic fate of prasugrel in mice, rats, and dogs
The disposition and metabolism of prasugrel, a thienopyridine prodrug and a potent inhibitor of platelet aggregation in vivo… 
2007
2007
[Prasugrel, a new thienopyridine].
The introduction of thienopyridines, specifically of clopidogrel, offered for the first time an orally active therapeutic… 
2006
2006
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL , A THIENOPYRIDINE ANTIPLATELET AGENT , WITH THE CYTOCHROMES P 450 Jessica
The biotransformation of prasugrel to R-138727 (2-[1-2-cyclopropyl1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)